Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for IEC/IRB Continuing Review Applications – V 2.0

Posted on By

BA-BE Studies: SOP for IEC/IRB Continuing Review Applications – V 2.0

Standard Operating Procedure for IEC/IRB Continuing Review Applications in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/018/2025
Supersedes SOP/BA-BE/018/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To outline the procedure for preparing and submitting Continuing Review Applications (CRA) to Institutional Ethics Committees (IEC) or Institutional Review Boards (IRB) for BA/BE studies that exceed the initial approval period or are ongoing.

2. Scope

This SOP applies to all ongoing BA/BE studies conducted by or for the sponsor, requiring annual or periodic ethics review as per ICH GCP, Schedule Y,

and institutional EC/IRB policies.

3. Responsibilities

  • Regulatory Affairs: Prepares and compiles the continuing review package and ensures timely submission.
  • Clinical Study Team: Provides current enrollment, study progress, and safety updates.
  • Principal Investigator (PI): Reviews, signs, and submits the CRA to the IEC/IRB.
  • Quality Assurance: Ensures all continuing review documents are archived and tracked.
See also  BA-BE Studies: SOP for Conducting Mock Runs for BA/BE - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring that all studies maintain uninterrupted IEC/IRB approval through timely submission of continuing review documents.

5. Procedure

5.1 Tracking of Review Timelines

  1. Record the initial IEC/IRB approval date in Annexure-1: Review Calendar Tracker.
  2. Set alert reminders 60 and 30 days prior to expiration of IEC/IRB approval.

5.2 Compilation of Continuing Review Package

  1. Prepare following documents:
    • Completed Continuing Review Application Form (CRA)
    • Current protocol version
    • Updated Investigator Brochure (if applicable)
    • Participant status report (enrolled, completed, withdrawn)
    • Summary of SAEs/SUSARs and deviations
    • Updated insurance certificate
    • Any new scientific information
  2. Ensure all documents are signed and version-controlled.

5.3 Internal Review and Approvals

  1. Regulatory Affairs reviews for completeness and compliance.
  2. PI reviews and signs cover letter and CRA form.
See also  BA-BE Studies: SOP for Preventive Maintenance of Clinical Equipment - V 2.0

5.4 Submission to IEC/IRB

  1. Submit within the timeline specified by the respective IEC/IRB (usually 30 days prior to expiry).
  2. Track date of submission and acknowledgment in Annexure-2: CRA Submission Log.

5.5 Response to IEC/IRB Comments

  1. Address any follow-up queries received from IEC/IRB within stipulated timelines.
  2. Document changes and correspondence in Annexure-3: CRA Communication Tracker.

5.6 Approval and Documentation

  1. On receipt of IEC/IRB approval:
    • Verify dates of extended approval period
    • Distribute to clinical team and file in eTMF

6. Abbreviations

  • IEC: Institutional Ethics Committee
  • IRB: Institutional Review Board
  • CRA: Continuing Review Application
  • SAE: Serious Adverse Event
  • eTMF: Electronic Trial Master File

7. Documents

  1. Review Calendar Tracker – Annexure-1
  2. CRA Submission Log – Annexure-2
  3. CRA Communication Tracker – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • Institutional EC Guidelines
See also  BA-BE Studies: SOP for Label Generation and Sample Barcode Management - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Review Calendar Tracker

Study Code Initial Approval Date Expiry Date Reminder Sent CRA Due Date
BE-031 10/05/2024 09/05/2025 Yes 09/04/2025

Annexure-2: CRA Submission Log

Submission Date Study Code EC Name Acknowledgment Received Status
05/04/2025 BE-031 IEC-Ahmedabad Yes Under Review

Annexure-3: CRA Communication Tracker

Date Study Code Query Summary Response Submitted Remarks
08/04/2025 BE-031 Clarification on AE reporting 10/04/2025 Revised CRA form attached

Revision History:

Revision Date Revision No. Details Reason Approved By
14/01/2022 1.0 Initial SOP Release New Procedure QA Head
17/04/2025 2.0 Added trackers, clarified timelines, harmonized with ICH GCP Audit Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Capsule: SOP for Testing Enteric Coated Capsules for Acid Resistance – V 2.0
Next Post: Tablets: SOP for Approving Equipment Cleaning Procedures – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version